Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC) Market Insights and Forecasts, 2017-2030

Source :: Plus Company Updates. August 5, 2020
Publication Year :: 2020
Abstract: DUBLIN: Research and Markets has issued the following press release: The 'Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast - 2030' drug pipelines has [...]

Subjects :: United States. Food and Drug Administration -- Reports
Merck KGaA -- Forecasts and trends
Novartis Pharma AG -- Forecasts and trends
Bristol-Myers Squibb Co. -- Forecasts and trends
Pfizer Inc. -- Forecasts and trends
AstraZeneca PLC -- Forecasts and trends
Durvalumab -- Reports -- Forecasts and trends
Ipilimumab -- Forecasts and trends -- Reports
BCG -- Forecasts and trends -- Reports
Bevacizumab -- Reports -- Forecasts and trends
Monoclonal antibodies -- Reports -- Forecasts and trends
Nivolumab -- Reports -- Forecasts and trends
Small cell lung cancer -- Forecasts and trends -- Reports
Pembrolizumab -- Forecasts and trends -- Reports
Epidemiology -- Reports -- Forecasts and trends
Pharmaceutical industry -- Forecasts and trends
Non-small cell lung cancer -- Reports -- Forecasts and trends
Market trend/market analysis
General interest
News, opinion and commentary
Opdivo (Medication) -- Reports
Keytruda (Medication) -- Reports

Tools